Biopharma Firm DURECT Nears Profitability Milestone DURECT Corporation is expected to achieve profitability by 2027, with analysts predicting a 60% annual growth rate. The company, focused on epigenetic treatments, has narrowed its financial losses over recent years. However, concerns remain over its high debt-to-equity ratio, posing risks to its financial stability.4